Welcome to our dedicated page for Pacific Biosc news (Ticker: PACB), a resource for investors and traders seeking the latest updates and insights on Pacific Biosc stock.
PacBio (Pacific Biosciences of California, Inc., NASDAQ: PACB) is a life science technology company focused on advanced genetic sequencing, and its news flow reflects developments across genomics research, collaborations, and financial performance. The company regularly issues press releases describing how its HiFi long-read sequencing platforms are being adopted in human health, rare disease research, and other genomics applications.
Recent PacBio news highlights planned collaborations with organizations such as the n-Lorem Foundation and EspeRare to apply long-read whole-genome sequencing in research on individualized antisense oligonucleotide therapies for ultra-rare and nano-rare genetic diseases. Other coverage includes projects where PacBio HiFi sequencing is used as a first-line whole-genome approach in studies of Sudden Unexplained Death in Childhood, and multi-center research through the HiFi Solves Consortium evaluating the clinical research utility of HiFi genomes in complex genomic regions.
Investors and researchers following PACB news will also find updates on technology advances, such as the community-developed CiFi long-read 3C method that integrates chromatin conformation capture with HiFi sequencing, and regulatory milestones achieved through partners like Berry Genomics in China with the Sequel II CNDx system. Financial news includes quarterly and preliminary annual revenue announcements, details on instrument and consumable performance, and commentary on new sequencing chemistries and assay portfolios.
This PACB news page on Stock Titan aggregates these types of announcements so readers can track PacBio’s research collaborations, technology developments, regional partnerships, and earnings-related updates in one place. Users interested in genomic sequencing, long-read technologies, and the business outlook for PacBio can review the latest press releases and historical news items to understand how the company’s platforms are being used and how management describes its progress.
Pacific Biosciences reported an impressive first quarter for 2021, achieving $29.0 million in revenue, an 86% increase from $15.6 million in Q1 2020. The company placed 41 Sequel II/IIe systems, boosting the total installed base to 244 systems compared to 125 a year prior. Instrument revenue surged to $14.9 million, while consumables revenue grew to $10.4 million. Despite increasing operating expenses of $46.7 million, the company faced a net loss of $87.4 million, primarily due to a $52 million repayment to Illumina. Cash reserves stood at $1,160.3 million.
Pacific Biosciences (NASDAQ: PACB) announced the nomination of Dr. Hannah Valantine for election to its Board of Directors as a Class II director during the 2021 Annual Meeting. Dr. Valantine, a prominent figure in cardiovascular medicine and workforce diversity, holds a professorship at Stanford University and has previously been the Chief Officer for Scientific Workforce Diversity at the NIH. Her expertise aligns with PacBio's strategic goals. Dr. Michael Hunkapiller will not seek re-election but will remain on the Board until the Annual Meeting.
Pacific Biosciences (PACB) has launched HiFi Sequencing and Software v10.1 for Sequel II and IIe Systems, enhancing genome sequencing accuracy to 99.9% (QV30). This release supports high-throughput sequencing, allowing the processing of thousands of genomes annually. A new protocol reduces DNA input by three-fold, facilitating work with limited samples. Developed alongside Children's Mercy Kansas City, the update boosts lab efficiency and includes workflows for SARS-CoV-2 genome analysis, indicating ongoing innovation in genetic research capabilities.
Pacific Biosciences (NASDAQ: PACB) announced the grant of stock options and restricted stock units to a new employee under its 2020 Inducement Equity Incentive Plan. The grant includes 80,000 shares as stock options and 40,000 shares as RSUs, effective April 19, 2021. The options have an exercise price of $29.61, matching the closing stock price on the effective date. Vesting for the options occurs over four years, while RSUs vest annually over four years. This initiative aims to attract talent to the company in compliance with Nasdaq rules.
Pacific Biosciences (NASDAQ: PACB) will conduct its Q1 2021 earnings call on April 29, 2021, at 4:30 PM ET. This conference will be available via webcast on the company's investor relations website. Pacific Biosciences specializes in long-read sequencing technology that enables comprehensive genetic analysis, supporting research in various fields including human health and microbiology. The Q1 financial results will be discussed during this call, highlighting the company's performance and future growth prospects.
Pacific Biosciences (NASDAQ: PACB) announced the grant of non-qualified stock options for 80,000 shares and restricted stock units (RSUs) for 40,000 shares to a newly hired employee under the 2020 Inducement Equity Incentive Plan, effective February 25, 2021. The options have an exercise price of $31.18, matching the stock's closing price on the effective date. Vesting for the options occurs over four years, while the RSUs vest annually over four years. This program is designed to attract talent by providing equity stakes in the company.
Pacific Biosciences (NASDAQ: PACB) announced its participation in two upcoming investor conferences.
The Cowen Annual Health Care Conference is set for March 1, 2021, at 1:20 p.m. EST, followed by the Barclays Global Healthcare Conference on March 10, 2021, at 2:25 p.m. EST. Live webcasts will be available on the company’s investor page, with replays accessible for 30 days post-presentation.
PACB specializes in advanced sequencing technology, empowering scientists globally in various fields to enhance research.
Pacific Biosciences (NASDAQ: PACB) announced an expanded partnership with Children’s Mercy Kansas City, adding four new Sequel IIe Systems for enhanced genome sequencing capacity. This investment aims to accelerate research in identifying disease-causing genetic variants, particularly for rare diseases. The ongoing collaboration has already yielded multiple new diagnoses, with a goal to complete HiFi whole genome sequencing for approximately 1,000 exome-negative cases in the next year. The partnership highlights the critical role of HiFi sequencing in improving diagnostic accuracy for children with undiagnosed conditions.
Pacific Biosciences (NASDAQ: PACB) announced that Labcorp has enhanced its commitment to HiFi sequencing technology by integrating new PacBio Sequel II Systems. This will enable the collection of thousands of complete SARS-CoV-2 genomes weekly, assisting the CDC in monitoring COVID-19 variants. Recently, they identified the B.1.351 variant in South Carolina and Virginia. The collaborative effort aims to bolster viral surveillance and improve public health responses globally. PacBio’s HiFi sequencing offers superior accuracy for tracking viral mutations.
Pacific Biosciences (NASDAQ: PACB) announced its financial results for Q4 2020, reporting a revenue of $27.1 million, a 42% increase sequentially but a 3% decrease year-over-year. Gross profit rose to $11.4 million despite a 12% decline from Q4 2019. Operating expenses reached $35.4 million, up from previous quarters. Notably, net income surged to $74.9 million, attributed to a $98 million fee from Illumina. The company also announced a $900 million investment from SoftBank and a partnership with Invitae for genome testing.